Stockscreener 앱 받기
87.49
4.89%
4.08
시간 외 거래:
87.49
전일 마감가:
$83.41
열려 있는:
$84.97
하루 거래량:
1.51M
Relative Volume:
1.33
시가총액:
$7.60B
수익:
$688.00K
순이익/손실:
$-168.74M
주가수익비율:
-37.11
EPS:
-2.3577
순현금흐름:
$-185.87M
1주 성능:
+16.53%
1개월 성능:
+16.78%
6개월 성능:
+164.64%
1년 성능:
+476.35%
1일 변동 폭
$83.17
$88.03
1주일 범위
$75.35
$88.03
52주 변동 폭
$14.00
$88.03
Spyre Therapeutics Inc Stock (SYRE) Company Profile
명칭
Spyre Therapeutics Inc
전화
(617) 651-5940
주소
221 CRESCENT STREET, WALTHAM
Compare SYRE vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
87.49 | 7.26B | 688.00K | -168.74M | -185.87M | -2.3577 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-14 | 개시 | Raymond James | Strong Buy |
| 2025-12-18 | 개시 | Mizuho | Outperform |
| 2025-12-17 | 개시 | Citigroup | Buy |
| 2025-09-26 | 개시 | Deutsche Bank | Buy |
| 2025-04-08 | 개시 | Leerink Partners | Outperform |
| 2025-03-18 | 개시 | Wolfe Research | Outperform |
| 2024-09-04 | 개시 | Wedbush | Outperform |
| 2024-07-16 | 개시 | Evercore ISI | Outperform |
| 2024-05-02 | 개시 | Robert W. Baird | Outperform |
| 2024-03-01 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | 개시 | BTIG Research | Buy |
| 2023-12-11 | 개시 | Guggenheim | Buy |
| 2023-12-11 | 개시 | Jefferies | Buy |
| 2020-05-04 | 개시 | Piper Sandler | Overweight |
| 2019-03-21 | 개시 | JP Morgan | Overweight |
| 2018-09-04 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | 개시 | Evercore ISI | Outperform |
| 2018-03-14 | 재확인 | Needham | Buy |
모두보기
Spyre Therapeutics Inc 주식(SYRE)의 최신 뉴스
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $103 - Moomoo
BTIG Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Raises Target Price to $112 - Moomoo
Spyre Therapeutics (SYRE) Reveals Promising Results from SKYLINE Trial - GuruFocus
Wedbush Raises Price Target on Spyre Therapeutics to $100 From $80 on Positive SPY002 Results, Maintains Outperform Rating - marketscreener.com
Spyre reports positive phase 2 trial results for UC drug By Investing.com - Investing.com South Africa
Spyre reports positive phase 2 trial results for UC drug - Investing.com UK
Spyre says bowel disease drug cuts inflammation in mid-stage trial - Reuters
Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients - The Manila Times
Spyre Therapeutics posts positive Phase 2 SKYLINE Part A results for SPY002, RHI -10.7 (p - TradingView
Spyre Therapeutics (NASDAQ: SYRE) posts positive Phase 2 SPY002 ulcerative colitis data - Stock Titan
JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $95 - Moomoo
SYRE Stock Marks Best Session In About 3 Years — Here’s Why - Stocktwits
Certain Common Stock of Spyre Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 14-JUN-2026. - marketscreener.com
Certain Restricted Stock Units of Spyre Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 14-JUN-2026. - marketscreener.com
SYRE completes enrollment in SKYWAY basket study on SPY072, stock up - MSN
Spyre Therapeutics stock hits 52-week high at 79.75 USD By Investing.com - Investing.com Nigeria
Spyre Therapeutics stock hits 52-week high at 79.75 USD - Investing.com
Capital International Investors Purchases 1,100,000 Shares of Spyre Therapeutics, Inc. $SYRE - MarketBeat
Spyre Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Spyre Therapeutics grants inducement awards to four employees - scanx.trade
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Spyre Therapeutics Grants Stock Options to Non-Executive Employees as Part of Equity Inducement Awards - Quiver Quantitative
Arrowpoint Investment Partners Singapore Pte. Ltd. Buys New Shares in Spyre Therapeutics, Inc. $SYRE - MarketBeat
SYRE Maintains Buy Rating by Deutsche Bank -- Price Target Raised to $115 - GuruFocus
SYRE Completes Enrollment in SKYWAY Basket Study on SPY072, Stock Up - sharewise.com
Deutsche Bank Adjusts Spyre Therapeutics Price Target to $115 From $102, Maintains Buy Rating - marketscreener.com
Spyre Therapeutics (SYRE): 12 Best High Short Interest Stocks With Highest Upside Potential - Insider Monkey
Deutsche Bank raises Spyre stock price target on competitor setback By Investing.com - Investing.com South Africa
Deutsche Bank raises Spyre stock price target on competitor setback - Investing.com
Spyre Therapeutics CFO Scott Burrows sells $532,936 in stock By Investing.com - Investing.com South Africa
Insider Sell: Cameron Turtle Sells 15,000 Shares of Spyre Therap - GuruFocus
Spyre Therapeutics CFO Scott Burrows sells $532,936 in stock - Investing.com India
Spyre Therapeutics CEO Cameron Turtle sells $1.06m in stock By Investing.com - Investing.com South Africa
Spyre Therapeutics CEO Cameron Turtle sells $1.06m in stock - Investing.com UK
Spyre Therapeutics CMO Sheldon Sloan sells $624,975 in stock By Investing.com - Investing.com South Africa
Spyre Therapeutics CMO Sheldon Sloan sells $624,975 in stock - Investing.com
Spyre Therapeutics (SYRE) CEO Turtle sells 15,000 shares in pre-set 10b5-1 trades - Stock Titan
Spyre Therapeutics (SYRE) CMO sells 8,333 shares, retains 313,334 options - Stock Titan
[144] Spyre Therapeutics, Inc. SEC Filing - Stock Titan
Spyre Therapeutics Inc (SYRE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Spyre Therapeutics Inc 주식 (SYRE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Sloan Sheldon | Chief Medical Officer |
Jun 03 '26 |
Sale |
75.00 |
8,333 |
624,975 |
0 |
| Turtle Cameron | Chief Executive Officer |
Jun 01 '26 |
Sale |
70.43 |
15,000 |
1,056,486 |
597,540 |
| Burrows Scott L | Chief Financial Officer |
Jun 01 '26 |
Option Exercise |
14.50 |
7,500 |
108,750 |
105,494 |
| Burrows Scott L | Chief Financial Officer |
Jun 01 '26 |
Sale |
71.06 |
7,500 |
532,937 |
97,994 |
2.60%
0.94%
자본화:
|
볼륨(24시간):